扶正升白口服液联合NP方案治疗晚期非小细胞肺癌的临床研究
|
摘要
目的:观察扶正升白口服液联合NP方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:采用反应变量-动态随机分组,使用翁模型,将60例患者随机分为治疗组36例、对照组24例。对照组给予NP方案化疗,21天为1个治疗周期,应用2个周期。治疗组在NP方案化疗的同时服用扶正升白口服液,2次/d,25 m L/次,直至化疗结束。结果:2组在瘤体变化方面比较,差异无统计学意义(P>0.05),但在毒副反应、生存质量、肿瘤标志物变化及生存分析等方面比较,差异有统计学意义(P<0.05)。结论:扶正升白口服液可有效对抗NP方案引起的副作用,改善生存质量,延长晚期NSCLC患者的生存时间。
Objective: To observe clinical effects of FuZheng ShengBai oral liquid combined with NP regimen in treating non small-cell lung cancer(NSCLC). Methods: Response variable dynamic random grouping method was adopted, and urn model was used, sixty patients were divided into 36 cases of the treatment group and 24 cases of the control group. The control group accepted chemotherapy according to NP regimen for two courses of the treatment, 21 days were one course of the treatment, the treatment group took FuZheng ShengBai oral liquid when they received chemotherapy, 25 m L each time, twice per day, till the end of chemotherapy. Results: The difference had no statistical meaning in the comparison of tumor body between both groups(P>0.05), and the differences presented statistical meaning in the comparisons of adverse reaction, life quality, tumor markers and survival analysis(P<0.05).Conclusion: FuZheng ShengBai oral liquid could effectively relieve NP regimen-induced adverse reaction, improve quality of life and prolong survival time of NSCLC patients at advanced stage.
Objective: To observe clinical effects of FuZheng ShengBai oral liquid combined with NP regimen in treating non small-cell lung cancer(NSCLC). Methods: Response variable dynamic random grouping method was adopted, and urn model was used, sixty patients were divided into 36 cases of the treatment group and 24 cases of the control group. The control group accepted chemotherapy according to NP regimen for two courses of the treatment, 21 days were one course of the treatment, the treatment group took FuZheng ShengBai oral liquid when they received chemotherapy, 25 m L each time, twice per day, till the end of chemotherapy. Results: The difference had no statistical meaning in the comparison of tumor body between both groups(P>0.05), and the differences presented statistical meaning in the comparisons of adverse reaction, life quality, tumor markers and survival analysis(P<0.05).Conclusion: FuZheng ShengBai oral liquid could effectively relieve NP regimen-induced adverse reaction, improve quality of life and prolong survival time of NSCLC patients at advanced stage.
引文
[1]Hammerschmidt S,Wirtz H.Lung cancer:current diagnosis and treatment[J].Dtsch Arztebl Int,2009,106(49):809-818.
[2]Molina JR,Yang P,Cassivi SD,et al.Non-small cell Lung cancer:epidemology,riskfaetors,treatment,and survivorshi P[J].Mayo Clin Proc,2008,83(5):584-594.
[3]中华人民共和国医政司.常见恶性肿瘤诊治规范[M].北京:中国协和医科大学出版社,1999:773.
[4]Mountain CF.Revision in the international system for staging lung cancer[J].Chest,1997,111(6):1710-1715.
[5]徐振哗,杨宇飞.肺癌中西医综合治疗[M].北京:人民卫生出版社,2002:451-456.
[6]陈智伟,廖美琳.RECIST标准在肿瘤治疗疗效评价中的应用[J].中国肿瘤,2004,13(10):616-618.
[7]查人俊,和长青,曾狄闻.现代肺癌诊断与治疗[J].2版.北京:人民军医出版社,1999:416-417.
[8]周清华.局部晚期非小细胞肺癌“个体化外科治疗”技术与策略[C].北京:第十一届全国肺癌学术大会论文集,2009:94-110.
[9]郑红刚,花宝金.朴炳奎辨治肺癌学术思想与经验辨析[J].中医杂志,2010,51(4):304-306.
[10]李维云,张玉环.黄芪的免疫研究进展[J].中国中医药杂志,2004,2(5):267-269.
[11]冯刚,孔庆志,黄冬生,等.薏苡仁注射液对小鼠移植性S180肉瘤血管形成抑制的作用[J].肿瘤防治研究,2004,31(4):229-231.
[12]Sun Yongxu,Liu Jicheng.Structural characterization of a water-soluble polysaccharide from the roots of codonopsis pilosula and its immunity activity[J].International Journal of Biologocal Macromolecules,2008,43:279-282.
[13]姬郁林,何金涛,周清华.丹参酮对人肺癌细胞株的抑制作用及其分子机理[J].中国肺癌杂志,2008,11(2):202-205.
[14]于春艳,李薇,刘玉和,等.白花蛇舌草提取物体外抗肿瘤作用及机制研究[J].北华大学学报,2004,5(5):412-416.
[15]王宇翎,张艳,方明,等.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报,2005,21(4):444-447.
[16]信淑珍,滕琳,欧阳修河.肺癌患者血清VEGF和EGF检测及其临床意义[J].医学临床研究,2008,25(11):1973-1975.
[17]王茸,赵毅,信洪杰,等.肺癌患者血清CEA、CA125和CA199测定的临床意义[J].中华现代内科学杂志,2006,9(3):1014-1015.
[18]丁明明.中药对肺癌细胞凋亡诱导基因表达的影响[J].西部中医药,2015,28(5):142-145.
[19]余红民,吴桂梅,潘智华等.GSNO对人肺腺癌A549细胞的作用[J].中国当代医药,2015,22(17):8-10.
[20]李环,王怀刚.灵芪胶囊对人肺腺癌A549细胞株凋亡基因Bcl-2表达的影响[J].中医药信息,2012,29(1):105-107.
[21]倪军,顾惠英,冯高华.扶正抗瘤方对肺癌化疗患者细胞免疫功能及生活质量的影响[J].西部中医药,2014,27(12):6-8.
[22]沈德义,沈敏琪,李炯.CYFRA2-1检测对非小细癌的临床意义[J].肿瘤研究与临床,2001,13(1):49-50.
[23]王人灵,方伟达,麦茂,等.老年性非小细胞肺癌调强适形放疗同期化疗的临床研究[J].中国当代医药,2015,22(17):35-37.
[24]张芳.培土生金法对气虚痰湿型肺癌化疗减毒增效的临床研究[J].西部中医药,2014,27(10):94-95.
[25]黄震洲.中西医结合治疗肺癌的研究进展[J].中医药信息,2012,29(3):129-132.
[26]何萍,徐昌维,单喜花,等.肿瘤异常蛋白对肺癌患者近期疗效的意义[J].河北中医,2014,36(12):1915-1916.
[27]黄震洲.中西医结合治疗肺癌的研究进展[J].中医药信息,2012,29(3):129-132.
[2]Molina JR,Yang P,Cassivi SD,et al.Non-small cell Lung cancer:epidemology,riskfaetors,treatment,and survivorshi P[J].Mayo Clin Proc,2008,83(5):584-594.
[3]中华人民共和国医政司.常见恶性肿瘤诊治规范[M].北京:中国协和医科大学出版社,1999:773.
[4]Mountain CF.Revision in the international system for staging lung cancer[J].Chest,1997,111(6):1710-1715.
[5]徐振哗,杨宇飞.肺癌中西医综合治疗[M].北京:人民卫生出版社,2002:451-456.
[6]陈智伟,廖美琳.RECIST标准在肿瘤治疗疗效评价中的应用[J].中国肿瘤,2004,13(10):616-618.
[7]查人俊,和长青,曾狄闻.现代肺癌诊断与治疗[J].2版.北京:人民军医出版社,1999:416-417.
[8]周清华.局部晚期非小细胞肺癌“个体化外科治疗”技术与策略[C].北京:第十一届全国肺癌学术大会论文集,2009:94-110.
[9]郑红刚,花宝金.朴炳奎辨治肺癌学术思想与经验辨析[J].中医杂志,2010,51(4):304-306.
[10]李维云,张玉环.黄芪的免疫研究进展[J].中国中医药杂志,2004,2(5):267-269.
[11]冯刚,孔庆志,黄冬生,等.薏苡仁注射液对小鼠移植性S180肉瘤血管形成抑制的作用[J].肿瘤防治研究,2004,31(4):229-231.
[12]Sun Yongxu,Liu Jicheng.Structural characterization of a water-soluble polysaccharide from the roots of codonopsis pilosula and its immunity activity[J].International Journal of Biologocal Macromolecules,2008,43:279-282.
[13]姬郁林,何金涛,周清华.丹参酮对人肺癌细胞株的抑制作用及其分子机理[J].中国肺癌杂志,2008,11(2):202-205.
[14]于春艳,李薇,刘玉和,等.白花蛇舌草提取物体外抗肿瘤作用及机制研究[J].北华大学学报,2004,5(5):412-416.
[15]王宇翎,张艳,方明,等.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报,2005,21(4):444-447.
[16]信淑珍,滕琳,欧阳修河.肺癌患者血清VEGF和EGF检测及其临床意义[J].医学临床研究,2008,25(11):1973-1975.
[17]王茸,赵毅,信洪杰,等.肺癌患者血清CEA、CA125和CA199测定的临床意义[J].中华现代内科学杂志,2006,9(3):1014-1015.
[18]丁明明.中药对肺癌细胞凋亡诱导基因表达的影响[J].西部中医药,2015,28(5):142-145.
[19]余红民,吴桂梅,潘智华等.GSNO对人肺腺癌A549细胞的作用[J].中国当代医药,2015,22(17):8-10.
[20]李环,王怀刚.灵芪胶囊对人肺腺癌A549细胞株凋亡基因Bcl-2表达的影响[J].中医药信息,2012,29(1):105-107.
[21]倪军,顾惠英,冯高华.扶正抗瘤方对肺癌化疗患者细胞免疫功能及生活质量的影响[J].西部中医药,2014,27(12):6-8.
[22]沈德义,沈敏琪,李炯.CYFRA2-1检测对非小细癌的临床意义[J].肿瘤研究与临床,2001,13(1):49-50.
[23]王人灵,方伟达,麦茂,等.老年性非小细胞肺癌调强适形放疗同期化疗的临床研究[J].中国当代医药,2015,22(17):35-37.
[24]张芳.培土生金法对气虚痰湿型肺癌化疗减毒增效的临床研究[J].西部中医药,2014,27(10):94-95.
[25]黄震洲.中西医结合治疗肺癌的研究进展[J].中医药信息,2012,29(3):129-132.
[26]何萍,徐昌维,单喜花,等.肿瘤异常蛋白对肺癌患者近期疗效的意义[J].河北中医,2014,36(12):1915-1916.
[27]黄震洲.中西医结合治疗肺癌的研究进展[J].中医药信息,2012,29(3):129-132.